TrialBritish journal of clinical pharmacology2022

Exposure-response relationships for the efficacy and safety of filgotinib and its metabolite GS-829845 in subjects with rheumatoid arthritis based on phase 2 and phase 3 studies.

Amy Meng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.